Sana Biotechnology Inc (SANA : NASDAQ)
Common Stock
$2.92
USD
+0.00 (%)
Last updated: 2026-09-17
Get SANA alerts:
SANA
Sana Biotechnology Inc
WealthAwesomePerformance
1 Day
-7.59%
1 Week
-7.89%
1 Month
-20.65%
YTD
-3.95%
Key Statistics
Market Cap
$874.13M
52W High
$6.55
52W Low
$2.61
P/E Ratio
-
50 Day MA
$3.56
200 Day MA
$3.69
Beta
2.13
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $3.08 | $3.27 | $3.06 | $3.10 | $3.10 | 2,916,011 |
| 9/16/2026 | $3.17 | $3.21 | $2.87 | $2.92 | $2.92 | 9,696,017 |
| 9/15/2026 | $3.20 | $3.20 | $3.08 | $3.16 | $3.16 | 2,472,695 |
| 9/14/2026 | $3.13 | $3.25 | $3.10 | $3.20 | $3.20 | 2,381,491 |
| 9/11/2026 | $3.13 | $3.17 | $3.01 | $3.13 | $3.13 | 3,280,174 |
| 9/10/2026 | $3.10 | $3.19 | $3.00 | $3.09 | $3.09 | 4,616,100 |
| 9/9/2026 | $3.51 | $3.52 | $3.16 | $3.17 | $3.17 | 8,650,600 |
| 9/8/2026 | $3.78 | $3.83 | $3.40 | $3.45 | $3.45 | 4,986,000 |
| 9/4/2026 | $3.86 | $3.92 | $3.81 | $3.85 | $3.85 | 1,239,200 |
| 9/3/2026 | $3.93 | $3.96 | $3.80 | $3.92 | $3.92 | 2,637,200 |
Analyst Price Targets
Based on 8 analysts covering SANA · as of Sep 17, 2026
Wall Street analysts forecast SANA stock price to rise 188.7% over the next 12 months.
Consensus
Buy4.38 / 5.00
Avg. Target
US$8.43
+188.7% Upside
Current Price
US$2.92
Last close
Analyst Breakdown (8 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SANA's historical volatility
30-Day Vol
80.3%
Annualized
90-Day Vol
72.3%
Annualized
Trend (90d)
-32.6%
Annualized drift
90d Mean
US$2.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$2.98 | US$2.26 – US$3.93 |
| 60 trading days | US$2.87 | US$1.94 – US$4.24 |
| 90 trading days | US$2.76 | US$1.71 – US$4.46 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-174.19M
- Profit Margin
- 0.00%
- ROE (TTM)
- -152.87%
- EPS (Diluted)
- -0.69
- Book Value
- 0.52
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About SANA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |